Giorgio Gaglia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Giorgio Gaglia has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Sandro Santagata
Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115, USA
26 shared publications Alex M. Jaeger
21 shared publications- Demi Sandel
Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
21 shared publications Jane B. Trepel
21 shared publicationsLauren Stopfer
21 shared publications- Luke Whitesell
Department of Molecular Genetics, University of Toronto
21 shared publications
Latest Publications
- Open Access
Single-cell neural network classifiers reveal that PM21 NK cell expansion is dependent on B cell signaling
In the field drug development ML/AI methods are being applied to improve drug production speed, costs, and reliability. In allogenic NK cell therapy production, one of the biggest challenges is the inherent variability in the donors that provide the starting material for NK cell expansion. In this study we performed PM21-mediated NK cell expansion on 26 donors, and in parallel performed single-cell transcriptomics on the same donor sample prior to expansion. Canonical differential expression analysis and cell state abundance did not highlight any significant difference between donors with high and low NK cell expansion yield. Instead, training neural networks classifiers for high-yield donors enabled identifying several highly predictive models with perfect cross-validation recall. Further investigation of the most predictive models unveiled a previously unknown role for B cell in supportive NK cell expansion. Overall, this study represents a blueprint for combining deep phenotyping and machine learning methods to unveil novel biology and improve the quality and speed of delivery of cell therapeutics to patients.
Open AccessSingle-cell neural network classifiers reveal that PM21 NK cell expansion is dependent on B cell signaling
In the field drug development ML/AI methods are being applied to improve drug production speed, costs, and reliability. In allogenic NK cell therapy production, one of the biggest challenges is the inherent variability in the donors that provide the starting material for NK cell expansion. In this study we performed PM21-mediated NK cell expansion on 26 donors, and in parallel performed single-cell transcriptomics on the same donor sample prior to expansion. Canonical differential expression analysis and cell state abundance did not highlight any significant difference between donors with high and low NK cell expansion yield. Instead, training neural networks classifiers for high-yield donors enabled identifying several highly predictive models with perfect cross-validation recall. Further investigation of the most predictive models unveiled a previously unknown role for B cell in supportive NK cell expansion. Overall, this study represents a blueprint for combining deep phenotyping and machine learning methods to unveil novel biology and improve the quality and speed of delivery of cell therapeutics to patients.
- Open Access
Estimating the impact of single-cell RNA sequencing of human tissues on drug target validation
Whilst the use of single-cell RNA sequencing (scRNA-seq) to understand target biology is well established, its predictive role in increasing the clinical success of therapeutic targets remains underexplored. Inspired by previous work on an association between genetic evidence and clinical success, we used retrospective analysis of known drug target genes to identify potential predictors of target clinical success from scRNA-seq data. We investigated whether successful drug targets are associated with cell type specific expression in a disease-relevant tissue (cell type specificity), and with cell type specific over-expression in disease patients compared to healthy controls (disease cell specificity). Analysing scRNA-seq data across diseases and tissues, we found that both cell type and disease cell specificity are features enriched in targets entering clinical development, and that cell type specificity in the disease-relevant tissue is robustly predictive of target progression from Phase I to II. While scRNA-seq analysis identifies a larger and complementary target space to that of direct genetic evidence, its association with specificity and drug approval appears less clear. We discuss how further expansion and harmonization of single-cell datasets, more sophisticated integration of this data in target discovery, and improved methods for tracking clinical trial outcomes could enhance our ability to leverage scRNA-seq insights in drug development in future.
Open AccessEstimating the impact of single-cell RNA sequencing of human tissues on drug target validation
Whilst the use of single-cell RNA sequencing (scRNA-seq) to understand target biology is well established, its predictive role in increasing the clinical success of therapeutic targets remains underexplored. Inspired by previous work on an association between genetic evidence and clinical success, we used retrospective analysis of known drug target genes to identify potential predictors of target clinical success from scRNA-seq data. We investigated whether successful drug targets are associated with cell type specific expression in a disease-relevant tissue (cell type specificity), and with cell type specific over-expression in disease patients compared to healthy controls (disease cell specificity). Analysing scRNA-seq data across diseases and tissues, we found that both cell type and disease cell specificity are features enriched in targets entering clinical development, and that cell type specificity in the disease-relevant tissue is robustly predictive of target progression from Phase I to II. While scRNA-seq analysis identifies a larger and complementary target space to that of direct genetic evidence, its association with specificity and drug approval appears less clear. We discuss how further expansion and harmonization of single-cell datasets, more sophisticated integration of this data in target discovery, and improved methods for tracking clinical trial outcomes could enhance our ability to leverage scRNA-seq insights in drug development in future.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
PBMC RNAseq Raw Transcript Counts
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
PBMC RNAseq Raw Transcript Counts
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
MC38 Tumors Pan Cancer Immune Profiling Codeset
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
MC38 Tumors Pan Cancer Immune Profiling Codeset
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
PBMC RNAseq DESeq2 Data Tables
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
PBMC RNAseq DESeq2 Data Tables
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
Clinical Data Pan Cancer Immune Profiling Codeset
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
Clinical Data Pan Cancer Immune Profiling Codeset